118 related articles for article (PubMed ID: 11505748)
1. [The assessment of urinary glycosaminoglycans (GAG) excretion during therapy of patients with progressive Graves' ophthalmopathy].
Pilarska K; Kulig G; Krzystolik Z
Pol Arch Med Wewn; 2001 Feb; 105(2):139-44. PubMed ID: 11505748
[TBL] [Abstract][Full Text] [Related]
2. Urinary glycosaminoglycans in Graves' ophthalmopathy.
Kahaly G; Schuler M; Sewell AC; Bernhard G; Beyer J; Krause U
Clin Endocrinol (Oxf); 1990 Jul; 33(1):35-44. PubMed ID: 2401097
[TBL] [Abstract][Full Text] [Related]
3. HPLC glycosaminoglycan analysis in patients with Graves' disease.
Hansen C; Fraiture B; Rouhi R; Otto E; Förster G; Kahaly G
Clin Sci (Lond); 1997 May; 92(5):511-7. PubMed ID: 9176026
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effects of intensive plasma exchange followed by immunosuppressive therapy in severe Graves' ophthalmopathy.
Glinoer D; Etienne-Decerf J; Schrooyen M; Sand G; Hoyoux P; Mahieu P; Winand R
Metab Pediatr Syst Ophthalmol (1985); 1988; 11(3):133-40. PubMed ID: 3205168
[TBL] [Abstract][Full Text] [Related]
5. [Usefulness of soluble ICAM-1 measurements for the evaluation of the disease activity and efficiency of therapy in patients with infiltrative Graves' ophthalmopathy].
Kulig G; Pilarska K; Kulig J; Krzyzanowska-Swiniarska B; Robaczyk M; Baraniak A
Pol Arch Med Wewn; 2002 Dec; 108(6):1161-9. PubMed ID: 12687928
[TBL] [Abstract][Full Text] [Related]
6. Determination of urinary mucopolysaccharides in Graves' disease.
Ursu H; Dumitrescu C; Bartoc R; Dumitriu L
Endocrinologie; 1984; 22(4):277-82. PubMed ID: 6240765
[TBL] [Abstract][Full Text] [Related]
7. Comparison of practical methods for urinary glycosaminoglycans and serum hyaluronan with clinical activity scores in patients with Graves' ophthalmopathy.
Martins JR; Furlanetto RP; Oliveira LM; Mendes A; Passerotti CC; Chiamolera MI; Rocha AJ; Manso PG; Nader HB; Dietrich CP; Maciel RM
Clin Endocrinol (Oxf); 2004 Jun; 60(6):726-33. PubMed ID: 15163337
[TBL] [Abstract][Full Text] [Related]
8. Beneficial effects of intensive plasma exchange followed by immunosuppressive therapy in severe Graves' ophthalmopathy.
Glinoer D; Etienne-Decerf J; Schrooyen M; Sand G; Hoyoux P; Mahieu P; Winand R
Acta Endocrinol (Copenh); 1986 Jan; 111(1):30-8. PubMed ID: 2868602
[TBL] [Abstract][Full Text] [Related]
9. The effect of somatostatin versus corticosteroid in the treatment of Graves' ophthalmopathy.
Kung AW; Michon J; Tai KS; Chan FL
Thyroid; 1996 Oct; 6(5):381-4. PubMed ID: 8936659
[TBL] [Abstract][Full Text] [Related]
10. Urinary glycosaminoglycans excretion in Graves' disease.
Priestley GC; Aldridge RD; Hurel S
Acta Derm Venereol; 1996 Sep; 76(5):368-70. PubMed ID: 8891010
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of soluble TNFalpha receptors (sTNFR1 and sTNFR2) during corticosteroid treatment in patients with Graves' ophthalmopathy.
Myśliwiec J; Kretowski A; Stepień A; Kinalska I
Immunol Invest; 2004 Feb; 33(1):61-8. PubMed ID: 15015833
[TBL] [Abstract][Full Text] [Related]
12. Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy.
Colao A; Lastoria S; Ferone D; Pivonello R; Macchia PE; Vassallo P; Bonavolonta G; Muto P; Lombardi G; Fenzi G
J Clin Endocrinol Metab; 1998 Nov; 83(11):3790-4. PubMed ID: 9814448
[TBL] [Abstract][Full Text] [Related]
13. Glycosaminoglycans in thyroid eye disease.
Kahaly G; Förster G; Hansen C
Thyroid; 1998 May; 8(5):429-32. PubMed ID: 9623737
[TBL] [Abstract][Full Text] [Related]
14. Increased sulfatation of orbital glycosaminoglycans in Graves' ophthalmopathy.
Hansen C; Rouhi R; Förster G; Kahaly GJ
J Clin Endocrinol Metab; 1999 Apr; 84(4):1409-13. PubMed ID: 10199787
[TBL] [Abstract][Full Text] [Related]
15. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
[TBL] [Abstract][Full Text] [Related]
16. [The influence of corticosteroids on IL-6/IL-6R system in patients with Graves' ophthalmopathy].
Myśliwiec J; Kretowski A; Topolska J; Stepień A; Kinalska I
Pol Arch Med Wewn; 2002 Aug; 108(2):739-44. PubMed ID: 12476893
[TBL] [Abstract][Full Text] [Related]
17. Glycosaminoglycans urinary excretion as a marker of the early stages of diabetic nephropathy and the disease progression.
Popławska-Kita A; Mierzejewska-Iwanowska B; Szelachowska M; Siewko K; Nikołajuk A; Kinalska I; Górska M
Diabetes Metab Res Rev; 2008; 24(4):310-7. PubMed ID: 18273859
[TBL] [Abstract][Full Text] [Related]
18. Urinary excretion of glycosaminoglycans in patients with postmenopausal osteoporosis.
Todorova S; Antov G; Levi S; Michailova A; Topalova N; Toneva Z
Horm Metab Res; 1992 Dec; 24(12):585-7. PubMed ID: 1478619
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic role of adhesion molecules sELAM-1 and sICAM-1 in glucocorticoid therapy of active ophthalmopathy].
Modelska-Ziółkiewicz A; Gembicki M; Bednarek J; Sowiński J
Pol Arch Med Wewn; 2003 May; 109(5):469-75. PubMed ID: 14768175
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of orbital irradiation combined with or without systemic high-dose or pulsed corticosteroids for Graves' ophthalmopathy.
Tsujino K; Hirota S; Hagiwara M; Fukada S; Takada Y; Hishikawa Y; Kono M; Abe M
Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):857-64. PubMed ID: 11020584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
